Literature DB >> 12537734

Opportunistic chlamydia screening; should positive patients be screened for co-infections?

V Harindra1, J M Tobin, G Underhill.   

Abstract

This study examines the requirement for testing patients for other sexually transmitted infections (STIs) and bacterial vaginosis (BV) when diagnosed with genital chlamydia during opportunistic screening. Data were collected on all patients participating in the Department of Health chlamydia screening pilot study in Portsmouth. One thousand two hundred and forty-five women and 490 men with genital chlamydia were seen in Portsmouth genitourinary medicine (GUM) department. Of the women screened in GUM, 28% had coexisting STIs and 21% had BV. The corresponding figures for those initially screened in the community were 4% and 17%. An increased number of female sexual partners of male patients (76%) and male partners of female patients (55%) of the GUM group had co-infections; 58% of male partners from the community group had another STI. The increased morbidity associated with these infections warrants screening of all patients with chlamydia for other STIs and BV.

Entities:  

Mesh:

Year:  2002        PMID: 12537734     DOI: 10.1258/095646202321020080

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Public health policies and management strategies for genital Chlamydia trachomatis infection.

Authors:  Kelly Shaw; David Coleman; Maree O'Sullivan; Nicola Stephens
Journal:  Risk Manag Healthc Policy       Date:  2011-05-19

2.  Population prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in the Netherlands. Should asymptomatic persons be tested during population-based Chlamydia screening also for gonorrhoea or only if chlamydial infection is found?

Authors:  Jan E A M van Bergen; Joke Spaargaren; Hannelore M Götz; Irene K Veldhuijzen; Patrick J E Bindels; Ton J Coenen; Jan Broer; Fetzen de Groot; Christian J P A Hoebe; Jan-Hendrik Richardus; Daniel van Schaik; Marije Verhooren
Journal:  BMC Infect Dis       Date:  2006-03-07       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.